Hs 611.T Cells
General information
| Description | Hs 611.T is a human classical Hodgkin lymphoma (cHL) cell line established from the lymph node of a 48-year-old Caucasian female. The line is derived from the T-cell-rich nodular sclerosis subtype of Hodgkin lymphoma, one of the most common cHL subtypes. Hs 611.T grows in suspension with lymphoblast-like morphology. Hodgkin lymphoma-derived cell lines are relatively rare owing to the scarcity of the malignant Hodgkin Reed-Sternberg (HRS) cells within the tumor mass; Hs 611.T provides a valuable in vitro model of cHL biology. Hs 611.T is applicable in Hodgkin lymphoma research including studies of HRS cell signaling, NF-κB pathway activity, JAK-STAT pathway regulation, surface antigen expression (including CD30, CD15, CD25), and responses to Hodgkin lymphoma-targeted therapies such as brentuximab vedotin (anti-CD30 ADC). The line is also used in immunological assays evaluating T cell suppression, cytokine secretion, and the tumor microenvironment interactions characteristic of cHL. As a BSL-2-classified cell line, it requires appropriate containment measures. |
|---|---|
| Organism | Human |
| Tissue | Lymph node |
| Disease | Hodgkin lymphoma |
| Metastatic site | Lymph node |
| Applications | Hodgkin lymphoma research; NF-κB and JAK-STAT pathway studies; CD30/CD15/CD25 expression assays; brentuximab vedotin efficacy studies; tumor microenvironment; immunotherapy research |
| Synonyms | Hs-611-T, Hs611T, HS611T |
Characteristics
| Age | 48 years |
|---|---|
| Gender | Female |
| Ethnicity | Caucasian |
| Morphology | Lymphoblast-like |
| Cell type | B lymphoblast |
| Growth properties | Suspension |
Regulatory Data
| Citation | Hs 611.T (Cytion catalog number 305915) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_0823 |
Biomolecular Data
Handling
| Culture Medium | DMEM, w: 4.5 g/L Glucose, w: 4 mM L-Glutamine, w: 3.7 g/L NaHCO3, w: 1.0 mM Sodium pyruvate (Cytion article number 820300a) |
|---|---|
| Supplements | Supplement the medium with 10% FBS |
| Dissociation Reagent | None |
| Doubling time | approx. 24 to 48 hours |
| Subculturing | Dilute the culture to 3–5 × 10⁵ cells/ml with fresh pre-warmed complete medium. Centrifugation (300×g, 5 min) may be used when medium exchange is required. Count viable cells before passaging to maintain optimal density. No enzymatic dissociation is required. |
| Split ratio | 1 to 3 |
| Seeding density | 2 to 4 x 105 cells/ml |
| Fluid renewal | Every 2 to 3 days |
| Freeze medium | As a cryopreservation medium, we use complete growth medium + 10% DMSO for adequate post-thaw viability. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Metastatic site: | Lymph node |
|---|
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 305915-010626 | Certificate of Analysis | 28. Jul. 2026 | 305915 |